Novartis’s Iptacopan (LNP023) Receives EMA’s Prime Designation for C3 Glomerulopathy
Novartis’s Iptacopan (LNP023) Receives EMA’s Prime Designation for C3 Glomerulopathy
Shots:
- EMA has granted PRIME designation for iptacopan (LNP023) in C3 glomerulopathy (C3G). PRIME designation enhancing the development of medicine targeting unmet medical need. Results of P-II interim analysis for iptacopan in C3G will be presented at ASN 2020
- Additionally, the company is investigating iptacopan in P-III study in PNH patients with residual anemia despite treatment with anti-C5 Ab therapy, planned to initiate in Dec’2020. The P-II data in PNH presented at EBMT
- Iptacopan is an oral, small-molecule, reversible inhibitor of factor B and has received FDA’s & EMA’s ODD in C3G, based on the preliminary data from the ph2 trial
Click here to read full press release/ article | Ref: Novartis | Image: BioProcess International